Is it safe to stop anti-PD-1 immunotherapy in patients with metastatic melanoma who achieve a complete response?

Michael A. Davies

doi:10.1200/JCO.20.00136

Is it safe to stop anti-PD-1 immunotherapy in patients with metastatic melanoma who achieve a complete response?

Michael A. Davies

Melanoma Medical Oncology

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Original language	English (US)
Pages (from-to)	1645-1647
Number of pages	3
Journal	Journal of Clinical Oncology
Volume	38
Issue number	15
DOIs	https://doi.org/10.1200/JCO.20.00136
State	Published - May 20 2020

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.20.00136

Cite this

@article{ff7058ea1b694ca5b0782d157594a654,

title = "Is it safe to stop anti-PD-1 immunotherapy in patients with metastatic melanoma who achieve a complete response?",

author = "Davies, {Michael A.}",

note = "Funding Information: M.A.D. is supported by the National Institutes of Health/National Cancer Institute (1R01CA187076-04, 1R01CA193970-01A1, 1U54CA224070-01, 1 P50 CA221703-01A1, and 2T32CA009666-21), the US Department of Defense/Congressionally Directed Medical Research Program (CA170374), the Cancer Prevention Research Institute of Texas (CPRIT; RP160183), the American Cancer Society, the Melanoma Research Alliance, the Melanoma Research Foundation, the AIM at Melanoma Foundation, the Cancer Fighters of Houston, the MD Anderson Cancer Center Multidisciplinary Research Program, and philanthropic contributions to the Melanoma Moon Shots Program of MD Anderson Cancer Center.",

year = "2020",

month = may,

day = "20",

doi = "10.1200/JCO.20.00136",

language = "English (US)",

volume = "38",

pages = "1645--1647",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",